10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab)

Recombinant Antibody
Catalog # APR10097

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P32970
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	21118

Additional Information


Target/Specificity	TNFSF7 / CD27L / CD70
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Name	CD70 (HGNC:11937)
Function	Expressed at the plasma membrane of B cells, it is the ligand of the CD27 receptor which is specifically expressed at the surface of T cells (PubMed:28011863, PubMed:28011864, PubMed:8387892). The CD70- CD27 signaling pathway mediates antigen-specific T cell activation and expansion which in turn provides immune surveillance of B cells (PubMed:28011863, PubMed:28011864).
Cellular Location	Cell membrane; Single-pass type II membrane protein


Images

Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.





The purity of Anti-TNFSF7 / CD27L / CD70 Reference Antibody (vorsetuzumab) is 99.29%, determined by SEC-HPLC.



Immobilized humanCD70-His at 2 μg/mL (30 μL/well) can bind Vorsetuzumab(P98623) with the EC50 of 0.001164 μg/mL.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.